Junchen Diao, Ph.D.

The mission of Bluejay Therapeutics is to develop innovative cures for infectious diseases with the first target indication of chronic HDV infection.

VISION ABOVE AND BEYOND Immvira was founded in May of 2015 by Prof. Bernard Roizman of University of Chicago and Prof. Grace Zhou formerly a Research Associate Professor at University of Chicago, Prof. Thomas Shenk of Princeton University, Prof. Richard Whitley of University of Alabama, Prof. Ralph Weichselbaum of University of Chicago. Our mission is to develop a broad range of anti-cancer therapies based on genetically engineered viruses and augmented by cancer specific immune factors or chemotherapeutic agents that can be delivered intratumorally or systemically. Our lead candidate, a oHSV encoding IL12 and anti-PD-1Ab (T3) is designed to be administered by direct injection into the tumor mass. In murine tests it is more potent and would be expected to lack the toxicity associated with the systemic administration of immunomodulators alone. Product line 1 already entered clinical trials in January of 2019.

Octagon Capital invests in public and private healthcare companies globally, with a focus in the US and China. We strive to build long-term investments and partner with our portfolio companies to support innovation. Octagon manages capital on behalf of global institutions including university endowments, non-profit foundations, family offices, pension funds and established asset managers.

The mission of Bluejay Therapeutics is to develop innovative cures for infectious diseases with the first target indication of chronic HDV infection.

VISION ABOVE AND BEYOND Immvira was founded in May of 2015 by Prof. Bernard Roizman of University of Chicago and Prof. Grace Zhou formerly a Research Associate Professor at University of Chicago, Prof. Thomas Shenk of Princeton University, Prof. Richard Whitley of University of Alabama, Prof. Ralph Weichselbaum of University of Chicago. Our mission is to develop a broad range of anti-cancer therapies based on genetically engineered viruses and augmented by cancer specific immune factors or chemotherapeutic agents that can be delivered intratumorally or systemically. Our lead candidate, a oHSV encoding IL12 and anti-PD-1Ab (T3) is designed to be administered by direct injection into the tumor mass. In murine tests it is more potent and would be expected to lack the toxicity associated with the systemic administration of immunomodulators alone. Product line 1 already entered clinical trials in January of 2019.

Octagon Capital invests in public and private healthcare companies globally, with a focus in the US and China. We strive to build long-term investments and partner with our portfolio companies to support innovation. Octagon manages capital on behalf of global institutions including university endowments, non-profit foundations, family offices, pension funds and established asset managers.